Janux Therapeutics (JANX) Stock Price, News & Analysis

Company Overview

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration. By activating key pathways of the innate immune response, these candidates aim to recruit and amplify antitumor T-cell activity while minimizing systemic exposure. Janux’s pipeline is advancing through early-stage clinical trials to evaluate safety, tolerability and preliminary signals of efficacy in a variety of solid tumors.

Based in San Diego, Janux leverages collaborations with contract research organizations and academic centers to support manufacturing and clinical development. The company’s leadership team comprises experienced immuno-oncology researchers and drug developers with backgrounds in biologics, formulation science and regulatory strategy. Janux continues to build its infrastructure and partnerships to accelerate the translation of its TLR agonists from preclinical research into potential new treatment options for cancer patients.

Key Stats

• Today's Range: $14.19 to $14.83
• 50-Day Range: $13.03 to $15.87
• 52-Week Range: $12.12 to $35.34
• Volume: 250,636 shs
• Average Volume: 1.20 million shs
• Market Capitalization: $888.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.85
• Consensus Rating: Moderate Buy

Janux Therapeutics Stock Analysis - MarketRank™

Janux Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 304th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Janux Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 1 strong buy rating, 9 buy ratings, 3 hold ratings, and 2 sell ratings.

Upside Potential

Janux Therapeutics has a consensus price target of $45.85, representing about 218.5% upside from its current price of $14.40.

Amount of Analyst Coverage

Janux Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.71) to ($2.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Janux Therapeutics is -7.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Janux Therapeutics is -7.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Janux Therapeutics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.12% of the float of Janux Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Janux Therapeutics has a short interest ratio ("days to cover") of 7.4.

Change versus previous month

Short interest in Janux Therapeutics has recently increased by 6.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Janux Therapeutics does not currently pay a dividend.

Dividend Growth

Janux Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.55

News Sentiment

Janux Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 31 news articles for Janux Therapeutics this week, compared to 3 articles on an average week.

Search Interest

18 people have searched for JANX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

9 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Janux Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,878.00 in company stock.

Percentage Held by Insiders

7.90% of the stock of Janux Therapeutics is held by insiders.

Percentage Held by Institutions

75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 5/14/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JANX
• CIK: 1817713
• Web: www.januxrx.com
• Phone: 858-751-4493
• Fax: N/A
• Employees: 30
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Janux Therapeutics: $45.85
• High Price Target: $100.00
• Low Price Target: $14.00
• Potential Upside/Downside: +218.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 15 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$113.62 million
• Net Margins: N/A
• Pretax Margin: -833.60%
• Return on Equity: -12.93%
• Return on Assets: -12.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 17.01
• Quick Ratio: 17.01

Sales & Book Value

• Annual Sales: $10 million
• Price / Sales: 87.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.44 per share
• Price / Book: 0.93

Miscellaneous

• Outstanding Shares: 60,980,000
• Free Float: 56,166,000
• Market Cap: $877.87 million
• Optionable: Optionable
• Beta: 2.58